English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  52848260    Online Users :  606
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"yu m l"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 91-115 of 237  (10 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-09-04T06:12:12Z Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses Yeh M.-L.; Hung C.-H.; Huang J.-F.; Liu C.-J.; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏 2021-09-04T06:12:11Z Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; Liu C.-H.; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:57Z APASL consensus statements and management algorithms for hepatitis C virus infection Omata M.; Kanda T.; Yu M.-L.; Yokosuka O.; Lim S.-G.; Jafri W.; Tateishi R.; Hamid S.S.; Chuang W.-L.; Chutaputti A.; Wei L.; Sollano J.; Sarin S.K.; JIA-HORNG KAO; McCaughan G.W.
臺大學術典藏 2021-09-04T06:11:54Z Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin Yu M.-L.; Liu C.-H.; Huang C.-F.; Tseng T.-C.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.-H.H.; Chuang W.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:52Z Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:51Z Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; JIA-HORNG KAO; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:49Z Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype Huang C.-F.; Yu M.-L.; JIA-HORNG KAO; Tseng T.-C.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Lin Z.-Y.; Chen S.-C.; Wang L.-Y.; Juo S.H.H.; Chuang W.-L.; Liu C.-H.
臺大學術典藏 2021-09-04T06:11:45Z Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study Dai C.-Y.; Tseng T.-C.; Wong G.L.H.; Huang J-F.; Wong V.W.S.; Liu C.-J.; Yu M.-L.; Chuang W.-L.; JIA-HORNG KAO; Yuen Chan H.L.; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:44Z Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: A randomized trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Chen S.-I.; Lin J.-W.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:25Z Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏 2021-09-04T06:11:23Z Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:22Z Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏 2021-09-04T06:11:12Z APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K.
臺大學術典藏 2021-09-04T06:11:12Z APASL consensus statements and recommendation on treatment of hepatitis C Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K.
臺大學術典藏 2021-09-04T06:10:54Z Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; JIA-HORNG KAO; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; JIA-HORNG KAO; Yu M.-L.; Chuang W.-L.; Chen C.-J.
臺大學術典藏 2021-09-04T05:17:13Z Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1 JIA-HORNG KAO; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M.
臺大學術典藏 2021-09-04T05:17:07Z Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan Hsieh M.-H.; Yeh M.-L.; Su T.-H.; Liu T.-W.; Huang C.-F.; Huang C.-I.; Wang S.-C.; Huang J.-F.; Dai C.-Y.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Liu C.-J.; Yu M.-L.
臺大學術典藏 2021-09-04T05:17:04Z Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study JIA-HORNG KAO; Yu M.-L.; Chen C.-Y.; Peng C.-Y.; Chen M.-Y.; Tang H.; Chen Q.; Wu J.J.
臺大學術典藏 2021-09-04T05:16:59Z Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:55Z Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏 2021-09-04T05:16:52Z APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Sarin S.K.; Omata M.
臺大學術典藏 2021-09-04T05:16:51Z Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:48Z Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; Liu C.-H.; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators
臺大學術典藏 2021-09-04T05:16:47Z APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Kadir Dokmeci A.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Ooka Y.; Yokosuka O.; Sarin S.K.; Omata M.
臺大學術典藏 2021-09-04T05:16:43Z Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; Su T.-H.; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; JIA-HORNG KAO; Yuen M.-F.; Yu M.-L.; Nguyen M.H.

Showing items 91-115 of 237  (10 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page